{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:43Z","timestamp":1787020183336,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770949"],"award-info":[{"award-number":["81770949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To describe the genetic and clinical features of nineteen patients from eleven unrelated Chinese pedigrees with\n                      <jats:italic>OPA1<\/jats:italic>\n                      -related autosomal dominant optic atrophy (ADOA) and define the phenotype-genotype correlations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Detailed ophthalmic examinations were performed. Targeted next-generation sequencing (NGS) was conducted in the eleven probands using a custom designed panel PS400. Sanger sequencing and cosegregation were used to verify the identified variants. The pathogenicity of gene variants was evaluated according to American College of Medical Genetics and Genomics (ACMG) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nineteen patients from the eleven unrelated Chinese ADOA pedigrees had impaired vision and optic disc pallor. Optical coherence tomography showed significant thinning of the retinal nerve fiber layer. The visual field showed varying degrees of central or paracentral scotoma. The onset of symptoms occurred between 3 and 24\u00a0years of age (median age 6\u00a0years). Eleven variants in\n                      <jats:italic>OPA1<\/jats:italic>\n                      were identified in the cohort, and nine novel variants were identified. Among the novel variants, two splicing variants c.984\u2009+\u20091_984\u2009+\u20092delGT, c.1194\u2009+\u20092\u00a0T\u2009&gt;\u2009C, two stop-gain variants c.1937C\u2009&gt;\u2009G, c.2830G\u2009&gt;\u2009T, and one frameshift variant c.2787_2794del8, were determined to be pathogenic based on ACMG. A novel splicing variant c.1316-10\u00a0T\u2009&gt;\u2009G was determined to be likely pathogenic. In addition, a novel missense c.1283A\u2009&gt;\u2009C (p.N428T) and two novel splicing variants c.2496G\u2009&gt;\u2009A and c.1065\u2009+\u20095G\u2009&gt;\u2009C were of uncertain significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Six novel pathogenic variants were identified. The findings will facilitate genetic counselling by expanding the pathogenic mutation spectrum of\n                      <jats:italic>OPA1<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-022-02546-0","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T09:48:54Z","timestamp":1658915334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autosomal dominant optic atrophy caused by six novel pathogenic OPA1 variants and genotype\u2013phenotype correlation analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jinfeng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-0905","authenticated-orcid":false,"given":"Bo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"6","key":"2546_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/hmg\/3.6.977","volume":"3","author":"H Eiberg","year":"1994","unstructured":"Eiberg H, Kjer B, Kjer P, Rosenberg T. Dominant optic atrophy (OPA1) mapped to chromosome 3q region I Linkage analysis. Hum Mol Genet. 1994;3(6):977\u201380.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2546_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0420.1996.tb00672.x","volume":"74","author":"B Kjer","year":"1996","unstructured":"Kjer B, Eiberg H, Kjer P, Rosenberg T. Dominant optic atrophy mapped to chromosome 3q region. II. Clinical and epidemiological aspects. Acta Ophthalmol Scand. 1996;74(1):3\u20137.","journal-title":"Acta Ophthalmol Scand"},{"issue":"8","key":"2546_CR3","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.ophtha.2009.12.038","volume":"117","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, Ah-Kine D, Hudson G, Czermin B, Taylor RW, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmol. 2010;117(8):1538\u201346 1546 e1531.","journal-title":"Ophthalmol"},{"issue":"4","key":"2546_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.survophthal.2009.10.002","volume":"55","author":"JA Fraser","year":"2010","unstructured":"Fraser JA, Biousse V, Newman NJ. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol. 2010;55(4):299\u2013334.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"2546_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ana.24410","volume":"78","author":"V Carelli","year":"2015","unstructured":"Carelli V, Musumeci O, Caporali L, Zanna C, La Morgia C, Del Dotto V, Porcelli AM, Rugolo M, Valentino ML, Iommarini L, et al. Syndromic parkinsonism and dementia associated with OPA1 missense mutations. Ann Neurol. 2015;78(1):21\u201338.","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"2546_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awq007","volume":"133","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, Caporali L, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133(Pt 3):771\u201386.","journal-title":"Brain"},{"issue":"1","key":"2546_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.25723","volume":"88","author":"L Caporali","year":"2020","unstructured":"Caporali L, Magri S, Legati A, Del Dotto V, Tagliavini F, Balistreri F, Nasca A, La Morgia C, Carbonelli M, Valentino ML, et al. ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy. Ann Neurol. 2020;88(1):18\u201332.","journal-title":"Ann Neurol"},{"issue":"3","key":"2546_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ana.25550","volume":"86","author":"N Jurkute","year":"2019","unstructured":"Jurkute N, Leu C, Pogoda HM, Arno G, Robson AG, Nurnberg G, Altmuller J, Thiele H, Motameny S, Toliat MR, et al. SSBP1 mutations in dominant optic atrophy with variable retinal degeneration. Ann Neurol. 2019;86(3):368\u201383.","journal-title":"Ann Neurol"},{"issue":"6","key":"2546_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00439-001-0633-y","volume":"109","author":"C Delettre","year":"2001","unstructured":"Delettre C, Griffoin JM, Kaplan J, Dollfus H, Lorenz B, Faivre L, Lenaers G, Belenguer P, Hamel CP. Mutation spectrum and splicing variants in the OPA1 gene. Hum Genet. 2001;109(6):584\u201391.","journal-title":"Hum Genet"},{"issue":"13","key":"2546_CR10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/hmg\/10.13.1369","volume":"10","author":"C Toomes","year":"2001","unstructured":"Toomes C, Marchbank NJ, Mackey DA, Craig JE, Newbury-Ecob RA, Bennett CP, Vize CJ, Desai SP, Black GC, Patel N, et al. Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy. Hum Mol Genet. 2001;10(13):1369\u201378.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2546_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbabio.2018.01.005","volume":"1859","author":"V Del Dotto","year":"2018","unstructured":"Del Dotto V, Fogazza M, Carelli V, Rugolo M, Zanna C. Eight human OPA1 isoforms, long and short: What are they for? Biochim Biophys Acta Bioenerg. 2018;1859(4):263\u20139.","journal-title":"Biochim Biophys Acta Bioenerg"},{"issue":"4","key":"2546_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/sj.cdd.4402048","volume":"14","author":"A Olichon","year":"2007","unstructured":"Olichon A, Elachouri G, Baricault L, Delettre C, Belenguer P, Lenaers G. OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Differ. 2007;14(4):682\u201392.","journal-title":"Cell Death Differ"},{"key":"2546_CR13","doi-asserted-by":"crossref","unstructured":"Lenaers G, Neutzner A, Le Dantec Y, Juschke C, Xiao T, Decembrini S, Swirski S, Kieninger S, Agca C, Kim US, et al. Dominant optic atrophy: Culprit mitochondria in the optic nerve. Prog Retin Eye Res.\u00a02021;83:100935.","DOI":"10.1016\/j.preteyeres.2020.100935"},{"issue":"1","key":"2546_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbamcr.2012.08.004","volume":"1833","author":"P Belenguer","year":"2013","unstructured":"Belenguer P, Pellegrini L. The dynamin GTPase OPA1: more than mitochondria? Biochim Biophys Acta. 2013;1833(1):176\u201383.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2546_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/ejhg.2013.72","volume":"22","author":"N Glockle","year":"2014","unstructured":"Glockle N, Kohl S, Mohr J, Scheurenbrand T, Sprecher A, Weisschuh N, Bernd A, Rudolph G, Schubach M, Poloschek C, et al. Panel-based next generation sequencing as a reliable and efficient technique to detect mutations in unselected patients with retinal dystrophies. Europ J Hum Genet. 2014;22(1):99\u2013104.","journal-title":"Europ J Hum Genet"},{"key":"2546_CR16","doi-asserted-by":"publisher","first-page":"635424","DOI":"10.3389\/fcell.2021.635424","volume":"9","author":"L Fu","year":"2021","unstructured":"Fu L, Li Y, Yao S, Guo Q, You Y, Zhu X, Lei B. Autosomal Recessive Rod-Cone Dystrophy Associated With Compound Heterozygous Variants in ARL3 Gene. Front Cell Dev Biol. 2021;9:635424.","journal-title":"Front Cell Dev Biol"},{"key":"2546_CR17","doi-asserted-by":"publisher","first-page":"634843","DOI":"10.3389\/fcell.2021.634843","volume":"9","author":"Q Zhu","year":"2021","unstructured":"Zhu Q, Rui X, Li Y, You Y, Sheng XL, Lei B. Identification of Four Novel Variants and Determination of Genotype-Phenotype Correlations for ABCA4 Variants Associated With Inherited Retinal Degenerations. Front Cell Dev Biol. 2021;9:634843.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2546_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/genes12040537","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Li Y, Qin L, Wu Y, Lei B. Autosomal Recessive Retinitis Pigmentosa Associated with Three Novel REEP6 Variants in Chinese Population. Genes (Basel). 2021;12(4):537.","journal-title":"Genes (Basel)"},{"issue":"7","key":"2546_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073\u201381.","journal-title":"Nat Protoc"},{"issue":"8","key":"2546_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nmeth0810-575","volume":"7","author":"JM Schwarz","year":"2010","unstructured":"Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575\u20136.","journal-title":"Nat Methods"},{"issue":"3","key":"2546_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O\u2019Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310\u20135.","journal-title":"Nat Genet"},{"issue":"7","key":"2546_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1101\/gr.3577405","volume":"15","author":"GM Cooper","year":"2005","unstructured":"Cooper GM, Stone EA, Asimenos G, Program NCS, Green ED, Batzoglou S, Sidow A. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 2005;15(7):901\u201313.","journal-title":"Genome Res"},{"issue":"5","key":"2546_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"3","key":"2546_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ophtha.2005.10.054","volume":"113","author":"M Nakamura","year":"2006","unstructured":"Nakamura M, Lin J, Ueno S, Asaoka R, Hirai T, Hotta Y, Miyake Y, Terasaki H. Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy. Ophthalmol. 2006;113(3):483-488.e481.","journal-title":"Ophthalmol"},{"issue":"1","key":"2546_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13023-019-1187-1","volume":"14","author":"B Le Roux","year":"2019","unstructured":"Le Roux B, Lenaers G, Zanlonghi X, Amati-Bonneau P, Chabrun F, Foulonneau T, Caignard A, Leruez S, Gohier P, Procaccio V, et al. OPA1: 516 unique variants and 831 patients registered in an updated centralized Variome database. Orphanet J Rare Dis. 2019;14(1):214.","journal-title":"Orphanet J Rare Dis"},{"issue":"Pt 2","key":"2546_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/brain\/awm298","volume":"131","author":"P Amati-Bonneau","year":"2008","unstructured":"Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, Campos Y, Rivera H, de la Aleja JG, Carroccia R, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy \u201cplus\u201d phenotypes. Brain. 2008;131(Pt 2):338\u201351.","journal-title":"Brain"},{"issue":"10","key":"2546_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.biocel.2009.04.012","volume":"41","author":"P Amati-Bonneau","year":"2009","unstructured":"Amati-Bonneau P, Milea D, Bonneau D, Chevrollier A, Ferre M, Guillet V, Gueguen N, Loiseau D, de Crescenzo MA, Verny C, et al. OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol. 2009;41(10):1855\u201365.","journal-title":"Int J Biochem Cell Biol"},{"issue":"Pt 8","key":"2546_CR28","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1093\/brain\/awu165","volume":"137","author":"T Bonifert","year":"2014","unstructured":"Bonifert T, Karle KN, Tonagel F, Batra M, Wilhelm C, Theurer Y, Schoenfeld C, Kluba T, Kamenisch Y, Carelli V, et al. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier. Brain. 2014;137(Pt 8):2164\u201377.","journal-title":"Brain"},{"issue":"4","key":"2546_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00438-021-01783-0","volume":"296","author":"X Xu","year":"2021","unstructured":"Xu X, Wang P, Jia X, Sun W, Li S, Xiao X, Hejtmancik JF, Zhang Q. Pathogenicity evaluation and the genotype-phenotype analysis of OPA1 variants. Mol Genet Genomics. 2021;296(4):845\u201362.","journal-title":"Mol Genet Genomics"},{"issue":"Pt 4","key":"2546_CR30","first-page":"1029","volume":"130","author":"MV Alavi","year":"2007","unstructured":"Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeyer U, Wehrl HF, Ruttiger L, Beck SC, Tonagel F, Pichler BJ, et al. A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain. 2007;130(Pt 4):1029\u201342.","journal-title":"Brain"},{"issue":"11","key":"2546_CR31","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/hmg\/ddm079","volume":"16","author":"VJ Davies","year":"2007","unstructured":"Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE, Nicols PP, Boulton ME, Votruba M. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet. 2007;16(11):1307\u201318.","journal-title":"Hum Mol Genet"},{"issue":"Pt 12","key":"2546_CR32","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/brain\/aws303","volume":"135","author":"E Sarzi","year":"2012","unstructured":"Sarzi E, Angebault C, Seveno M, Gueguen N, Chaix B, Bielicki G, Boddaert N, Mausset-Bonnefont AL, Cazevieille C, Rigau V, et al. The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. Brain. 2012;135(Pt 12):3599\u2013613.","journal-title":"Brain"},{"issue":"1","key":"2546_CR33","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/s41598-018-20838-8","volume":"8","author":"E Sarzi","year":"2018","unstructured":"Sarzi E, Seveno M, Piro-Megy C, Elziere L, Quiles M, Pequignot M, Muller A, Hamel CP, Lenaers G, Delettre C. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model. Sci Rep. 2018;8(1):2468.","journal-title":"Sci Rep"},{"key":"2546_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.phrs.2018.02.018","volume":"131","author":"V Del Dotto","year":"2018","unstructured":"Del Dotto V, Fogazza M, Lenaers G, Rugolo M, Carelli V, Zanna C. OPA1: How much do we know to approach therapy? Pharmacol Res. 2018;131:199\u2013210.","journal-title":"Pharmacol Res"},{"issue":"4","key":"2546_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1586\/ern.13.19","volume":"13","author":"T Neuhann","year":"2013","unstructured":"Neuhann T, Rautenstrauss B. Genetic and phenotypic variability of optic neuropathies. Expert Rev Neurother. 2013;13(4):357\u201367.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"2546_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jcp.20950","volume":"211","author":"A Olichon","year":"2007","unstructured":"Olichon A, Landes T, Arnaune-Pelloquin L, Emorine LJ, Mils V, Guichet A, Delettre C, Hamel C, Amati-Bonneau P, Bonneau D, et al. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis. J Cell Physiol. 2007;211(2):423\u201330.","journal-title":"J Cell Physiol"},{"key":"2546_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.mito.2018.07.006","volume":"46","author":"M Ham","year":"2019","unstructured":"Ham M, Han J, Osann K, Smith M, Kimonis V. Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy. Mitochondrion. 2019;46:262\u20139.","journal-title":"Mitochondrion"},{"issue":"10","key":"2546_CR38","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1167\/iovs.14-14953","volume":"55","author":"J Chen","year":"2014","unstructured":"Chen J, Xu K, Zhang X, Jiang F, Liu L, Dong B, Ren Y, Li Y. Mutation screening of mitochondrial DNA as well as OPA1 and OPA3 in a Chinese cohort with suspected hereditary optic atrophy. Invest Ophthalmol Vis Sci. 2014;55(10):6987\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2546_CR39","first-page":"292","volume":"19","author":"Y Chen","year":"2013","unstructured":"Chen Y, Jia X, Wang P, Xiao X, Li S, Guo X, Zhang Q. Mutation survey of the optic atrophy 1 gene in 193 Chinese families with suspected hereditary optic neuropathy. Mol Vis. 2013;19:292\u2013302.","journal-title":"Mol Vis"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02546-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02546-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02546-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T13:47:48Z","timestamp":1676209668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02546-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2546"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02546-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"28 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Subjects older than 16 gave their informed consent for inclusion before they participated in the study. For children aged between 4 and 16, informed consent from their parent or legal guardian was obtained. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Henan Eye Hospital (HNEECKY-2019 (15), 15 October 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients (or their parents or legal guardian in the case of children under 16) to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}